Leigh disease is a genetically heterogeneous, neurodegenerative disorder of childhood that is caused by defects of either the nuclear or mitochondrial genome. Here, we report the molecular genetic findings in a patient with neuropathological hallmarks of Leigh disease and complex I deficiency. Direct sequencing of the seven mitochondrial DNA (mtDNA)-encoded complex I (ND) genes revealed a novel missense mutation (T12706C) in the mitochondrial ND5 gene. The mutation is predicted to change an invariant amino acid in a highly conserved transmembrane helix of the mature polypeptide and was heteroplasmic in both skeletal muscle and cultured skin fibroblasts. The association of the T12706C ND5 mutation with a specific biochemical defect involving complex I is highly suggestive of a pathogenic role for this mutation.
Introduction
Leigh disease is a neurodegenerative condition with a variable clinical course, though it usually presents during early childhood. It is characterised neuropathologically by symmetrical vasculonecrotic lesions, primarily in the brainstem and basal ganglia, though there may also be abnormalities in the spinal cord, cerebellum, other parts of the brain, optic and peripheral nerves. In most patients, the condition is caused by defects of mitochondrial oxidative phosphorylation, the commonest biochemical abnormalities involving the pyruvate dehydrogenase complex, cytochrome c oxidase (COX) and complex I. 1, 2 Consequently, both nuclear gene defects and mutations of the mitochondrial genome (mtDNA) have been characterised in patients with Leigh disease. 1 A number of mitochondrial DNA (mtDNA) mutations have recently been reported in association with a specific complex I deficiency in several of these patients. These have included mutations in the tRNA Leu(UUR) gene, 3 and a G14459A transition in the ND6 gene that has previously been characterised in patients with Lebers hereditary optic neuropathy (LHON) and dystonia. 4 The association of this mutation with Leigh disease therefore raises the possibility that mutations in other mtDNA-encoded structural complex I genes may play a role in the pathogenesis of this disorder. Here, we report the identification of a novel mtDNA mutation in the ND5 gene in a patient with Leigh disease and complex I deficiency. Muscle histology and biochemistry Succinate dehydrogenase (SDH) and cytochrome c oxidase (COX) activities were determined histochemically in cryostat sections (8 mm) of frozen muscle. Mitochondrial fractions were isolated from skeletal muscle and cultured skin fibroblasts, and the activities of the individual respiratory chain complexes and the matrix marker citrate synthase were determined spectrophotometrically as previously described.
Materials and methods
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Mitochondrial DNA analysis Total DNA was extracted from both skeletal muscle and fibroblasts using standard procedures. Direct sequencing of all seven mitochondrially-encoded complex I genes was performed as previously described, using M13-tagged PCR primers and BigDye terminator cycle sequencing chemistries (Applied Biosystems, Foster City, CA, USA). 6 The level of mutated mtDNA was determined by`last hot cycle' PCR ± RFLP analysis using primers corresponding to nt positions 12284 ± 12302 (forward) and nt positions 12815 ± 12795 (reverse) to PCR-amplify a 532-bp fragment. Following 30 cycles of amplification, an additional cycle was performed in the presence of 5 mCi [a-32 P]dCTP (3000 Ci/mmol).
Labelled products were precipitated and equal amounts (2000 counts) digested with 10 U MnlI (New England Biolabs (UK) Ltd, Hitchin). Restriction fragments were separated through an 6% nondenaturing polyacrylamide gel, dried onto a support and analysed with ImageQuant software following exposure to a Storm 1 PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA). A single MnlI recognition site in the wild type product generates fragments of 403 and 129 bp. The T12706C transition creates an additional MnlI site, cutting the 403 bp fragment into smaller products of 303 and 100 bp, permitting the discrimination of wild-type and mutant mtDNA molecules (see Figure 1 ).
Results
Muscle histology revealed minor non-specific changes and the histochemical activities of cytochrome c oxidase (COX) and succinate dehydrogenase were normal. Respiratory chain studies revealed a specific defect in complex I activity in muscle mitochondria (33% of normal control values). The activities of respiratory chain complexes II, III and IV were all entirely normal (results not shown). The biochemical defect was also expressed in cultured skin fibroblasts, but to a lesser extent (49% of normal control values).
Southern analysis of muscle DNA did not reveal large-scale mtDNA rearrangements, and a subsequent screen for mtDNA mutations known to be associated with Leigh disease (T8993G, T8993C, A8344G) and LHON (G3460A, G11778A, T14484C) proved negative. Direct sequencing of all seven mitochondrially-encoded complex I genes revealed a number of homoplasmic polymorphic variants (MITOMAP database, http://www.gen.emory.edu/mitomap.html) and a single heteroplasmic change from the revised Cambridge reference sequence, a T to C transition at position 12706 of the ND5 gene (Figure 1 ). The ND5 mutation was confirmed as heteroplasmic and shown to be present at levels of 43% mutant load in skeletal muscle and 30% mutant load in skin fibroblasts by PCR ± RFLP analysis (see Figure 1) . Furthermore, the T12706C mutation was not represented in a database of 754 human mitochondrial genomes (MitoKor Mitochondrial SNP Database, personal communication) or detected in 35 patients presenting with mitochondrial encephalomyopathies in whom the causative genetic abnormality was unknown.
Discussion
We have identified a novel missense T12706C mutation in the mitochondrial ND5 gene in a patient with Leigh disease, and present several lines of evidence to support its aetiologic role. First, it was heteroplasmic and was detectable at higher levels in post-mitotic skeletal muscle than an unaffected tissue (fibroblasts), suggestive of a correlation with the severity of the clinical symptoms. Unfortunately, neuropathological tissue samples were not available for molecular genetic analysis. Second, this mutation was not detected in a large database of 754 human mitochondrial genomes or 35 disease controls and has not been reported previously either in association with optic atrophy or as a common polymorphic variant. Together these data suggest that the T12706C transition does not occur frequently in the general population and provides further evidence of pathogenicity.
Third, the T12706C transition changes an amino acid (phenylalanine-124) in a highly conserved region of the human ND5 protein that is predicted to form one of eighteen transmembrane helices in the protein by structural (Tmpred program) analysis (http://searchlauncher.bcm.tmc.edu/seqsearch/struc-predict.html). Indeed, evolutionary comparison of mitochondrial ND5 sequences indicate that phenylalanine-124 is invariant in all homologous genes (see Table 1 ). 7 The mutation predicts an amino acid change to leucine, which also has a hydrophobic side-chain. Whilst the effect of this specific amino acid change on ND5 folding or function cannot be anticipated, a phenylalanine to leucine substitution has been documented previously as pathogenic in a patient with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) with a heteroplasmic COX III gene mutation.
Fourth, and most compelling, the T12706C ND5 mutation clearly associates with a specific biochemical defect involving complex I. The low mutation load of only 43% in skeletal muscle results in a loss of more than 65% of control enzyme activity, suggesting that the mutation exhibits a low biochemical threshold for disease expression. This is consistent with other mtDNA-encoded structural gene mutations, 9 and is in agreement with recent findings in a mouse cell variant carrying a heteroplasmic, nonsense ND5 mutation that demonstrated exquisite control over complex Idependent respiration by this subunit. 10 This report adds to the growing number of mtDNA mutations involving complex I subunits that have recently been identified in patients with Leigh disease. One of these (G13513A) also resides in the ND5 gene and appears to cause pathology at relatively low levels of heteroplasmy. The G13513A mutation was first described in association with the mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) phenotype, and has subsequently been reported in patients with LHON 11 as well as Leigh disease (DM Kirby, personal communication). The G14459A ND6 LHON/dystonia mutation has also been described at very high levels (495%) in three patients with Leigh disease and complex I deficiency. 4 Interestingly, there was no evidence of optic atrophy in these patients or obvious correlation of the mutant mtDNA load with clinical features. Our studies in this patient further illustrate the genetic diversity of Leigh disease, and reinforce the importance of maternally inherited mtDNA mutations in the aetiology of this disorder, particularly in those patients who present as adults 12 . Unfortunately, we were not able to study the level of mutation in other maternal relatives as the family declined further investigations and the invitation to attend genetic counselling. Despite the absence of specific treatments for patients with mtDNA disease, we believe that the current momentum to identify and characterise the molecular defects in these patients must be maintained, as this information will have considerable implications for their families both in terms of prognostic advice and genetic counselling. 
Evolutionary comparison of the highly conserved region on ND5 sequence (conserved residues are unshaded). The amino acid substitution (phenylalanine to leucine) at postition 124 is shown in bold)
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